Berlex Signs License Agreement with GeneGo
News Mar 16, 2006
The license provides researchers at Berlex and its German parent company with use of the MetaCore platform for analysis of gene expression, proteomic, metabolic and other high-throughput data in multiple therapeutic areas, including oncology, and in diagnostic applications.
"We are very pleased to bring MetaCore into our research," said Hugh Salamon, senior computational biologist, Berlex.
"It is essential to exploit curation of scientific findings given the large body of knowledge relevant to therapeutic research. GeneGo is providing us with an important view of current knowledge of mammalian signaling, metabolism, drugs and diseases through the MetaCore platform."
"We are very pleased that researchers at Berlex Biosciences, the US research center for Berlex, will be using MetaCore and to have the company as a GeneGo customer," said Julie Bryant, Vice President of Business Development at GeneGo.
"Berlex researchers will be among more than 140 unique accounts and thousands of users. Feedback from such partnerships help us enhance MetaCore as a versatile, multi-purpose data mining tool applicable in diverse life science projects."
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.